A HUWE1 regulatory helix gates ASCL1 degradation through its C-terminal phospho-degron in small cell lung cancer
Lineage-defining transcription factors are key oncogenic drivers but remain difficult to target pharmacologically due to the absence of ligandable pockets. The molecular rules governing substrate recognition by large HECT ubiquitin ligases also remain incompletely understood, limiting efforts to exploit these enzymes for targeted protein degradation. Here we combine genome-wide CRISPR knockout screening with base editor tiling screens at amino acid resolution, both coupled to an endogenous knock-in reporter of the SCLC lineage oncogenic transcription factor ASCL1, to systematically interrogate the mechanisms governing its degradation. These complementary screens unbiasedly identify the HECT ubiquitin ligase HUWE1 as the dominant regulator of ASCL1 stability in small cell lung cancer (SCLC) and resolve a conserved C-terminal phospho-degron centered on Ser207 and terminal Trp/Phe residues that are required for HUWE1 docking and ubiquitin-mediated degradation. Unexpectedly, base editor screening further uncovers a previously unrecognized regulatory module within HUWE1: a short negatively charged helix that functions as an autoinhibitory gate controlling access of phospho-degron substrates to HUWE1. Charge-flipping mutations within this regulatory helix relieve autoinhibition and accelerate degradation of multiple HUWE1 phospho-degron substrates, including ASCL1 and the canonical HUWE1 substrate DDIT4. Stabilization of ASCL1 through degron disruption paradoxically impairs SCLC proliferation, revealing that dynamic proteasome-coupled turnover is required for transcription factor function. Together, these findings reveal molecular rules governing HUWE1 phospho-degron recognition and identify a regulatory gate controlling substrate engagement. They also illustrate a generalizable strategy for resolving degradation mechanisms of undruggable transcription factors in their endogenous cellular context.
Authors
- E. Schmid (ORCID: https://orcid.org/0000-0002-4662-5298)
- Sumaiya Iqbal (ORCID: https://orcid.org/0000-0001-7700-4374)
- João A. Paulo (ORCID: https://orcid.org/0000-0002-4291-413X)
- Keita Masuzawa (ORCID: https://orcid.org/0000-0002-0549-8966)
- Kevin Dong (ORCID: https://orcid.org/0000-0002-2341-8472)
- Brian B. Liau (ORCID: https://orcid.org/0000-0002-2985-462X)
- Matthew G. Oser (ORCID: https://orcid.org/0000-0003-2047-0969)
- Leslie Duplaquet (ORCID: https://orcid.org/0000-0002-6544-0432)
- Suzan Lazo (ORCID: https://orcid.org/0000-0002-6678-9847)
- Tianchu Wang (ORCID: https://orcid.org/0000-0003-3870-3951)
- Shilpa Singh (ORCID: https://orcid.org/0000-0002-2648-2621)
- Deli Hong
- Ka Yang
- John G. Doench (ORCID: https://orcid.org/0000-0002-3707-9889)
- Michael Y. Tolstorukov
- Cyrus Jin
- Katherine A. Donovan
- Matthew A. Booker
- Calvin XiaoYang Hu
- Steven P. Gygi
- Eric S. Fischer
- Yixiang Li
- Xinyue Li
- Yoochan Myung
- Ting Peng
Institutions
- Broad Institute (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Harvard University Press (US)
- Dana-Farber Cancer Institute (US)
- Dana-Farber Brigham Cancer Center (US)
Publication Details
- Journal
- Genes & Development
- Published
- 2026-09-10
- DOI
- https://doi.org/10.1101/gad.353898.126
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- preprint